+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study



Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study



Clinical Therapeutics 31(10): 2242-2248



Finasteride, an inhibitor of the steroid 5alpha-reductase, has been approved for the treatment of benign prostatic hyperplasia and androgenetic alopecia. An orally disintegrating tablet (ODT) 5-mg formulation of finasteride was recently developed. Information regarding its pharmacokinetics and bioequivalence was required to assess the efficacy and safety of this formulation before marketing it in China. The aims of this study were to compare the bioavailability of finasteride ODTs and standard tablets in healthy adult male Han Chinese volunteers and to determine whether any observed differences exceeded Chinese regulatory guidelines for bioequivalence. This single-dose, randomized, open-label, 2-way crossover trial was conducted in China. Healthy adult male Han Chinese volunteers were enrolled. Participants were randomly assigned to receive 10 mg of either the ODT or standard tablet formulation, followed by a 1-week washout period and administration of the alternate formulation. Doses were administered after a 12-hour overnight fast. For analysis of pharmacokinetic properties, including C(max), AUC(0-24), and AUC(0-infinity), blood samples were obtained at 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 8, 11, 14, and 24 hours after administration. The formulations were to be considered bioequivalent if calculations of the 90% CI for the ratio of the means of the measures for the test and reference formulations fell within bioequivalence limits, 80% to 125%, for logarithmic (log) transformation of C(max) and AUC, and if Schuirmann's two 1-sided tests showed P < 0.05. Tolerability was assessed using vital sign measurements (ie, blood pressure, body temperature, heart rate, and respiratory rate), laboratory analysis (ie, hematology, blood biochemistry, hepatic function, and urinalysis), and interviews with participants. Twenty-four men (mean [SD] age, 22.0 [1.2] years [range, 20-24 years]; weight, 63.5 [4.6] kg [range, 55-70 kg]; height, 172.8 [4.4] cm [range, 164-180 cm]) were enrolled in this study, and 24 (12 each randomized to receive the ODT or standard tablet first) completed it. No period or sequence effects were observed. The 90% CIs for the log-transformed C(max), AUC(0-24), and AUC(0-infinity) values were 86.8 to 106.8, 95.1 to 119.1, and 96.2 to 117.5, respectively (all, P < 0.05). The Wilcoxon rank sum test of T(max) found a significant difference between the ODT formulation (mean [SD], 2.40 [0.47] hours) and standard tablet formulation (1.98 [0.63] hours). No adverse events were reported by the volunteers or found in clinical laboratory testing during the study. In this single-dose study, based on the rate and extent of absorption, the ODT (ie, test) and standard tablet (ie, reference) formulations of finasteride met the regulatory criteria for bioequivalence in these fasting healthy adult male Han Chinese volunteers. However, a significant difference was found for T(max) between the test and reference formulations. Both formulations were well tolerated. ClinicalTrials. gov identifier: 2005L02216.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051805282

Download citation: RISBibTeXText

PMID: 19922895

DOI: 10.1016/j.clinthera.2009.09.015


Related references

Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Clinical Therapeutics 32(7): 1387-1395, 2010

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clinical Therapeutics 31(10): 2224-2232, 2010

Pharmacokinetic and bioequivalence comparison between orally disintegrating and conventional tablet formulations of flurbiprofen: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male volunteers. Clinical Therapeutics 31(8): 1787-1795, 2010

Relative bioavailability of two formulations of nevirapine 200-mg tablets in healthy Chinese male volunteers: a single-dose, randomized-sequence, open-label, two-way crossover study. Clinical Therapeutics 32(13): 2258-2264, 2011

Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Clinical Therapeutics 32(7): 1396-1407, 2010

Comparative fasting bioavailability of dispersible and conventional tablets of risperidone: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy male Chinese volunteers. Clinical Therapeutics 34(6): 1432-1439, 2012

Pharmacokinetics and bioequivalence evaluation of two acipimox tablets: a single-dose, randomized-sequence, two-way crossover study in healthy Chinese male volunteers. Drug Research 63(2): 79-83, 2013

Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Clinical Therapeutics 31(9): 1992-2001, 2010

The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Clinical Therapeutics 32(9): 1674-1680, 2011

Relative bioavailability of generic and branded acetylcysteine effervescent tablets: A single-dose, open-label, randomized-sequence, two-period crossover study in fasting healthy Chinese male volunteers. Clinical Therapeutics 32(12): 2097-2105, 2011

Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Current Therapeutic Research, Clinical and Experimental 65(1): 34-46, 2004

Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers. Plos One 11(3): E0150661, 2016

Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. Clinical Therapeutics 30(9): 1651-1657, 2008

Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers. Clinical Therapeutics 30(10): 1831-1843, 2008

Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clinical Therapeutics 32(7): 1408-1418, 2010